Engflag

Surfaz SN

Quick links to important sections

Surfaz SN

Surfaz SN_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Surfaz SN

Property Description
Active Ingredients Betamethasone, Clotrimazole, Neomycin sulfate
Form Cream or Ointment (Topical)
Pharmacological Class Corticosteroid, Antifungal, Antibiotic Combination
Common Use Management of inflammatory, mixed skin infections
Origin Synthetic/Semisynthetic

1. Identity and Classification: What Type of Medicine is Surfaz SN?

Surfaz SN is a powerful triple combination topical preparation intended solely for external application to the skin, classifying it as a dermatological medicine. This formulation integrates three distinct active pharmaceutical ingredients (APIs): a Topical Corticosteroid (Betamethasone), an Imidazole Antifungal (Clotrimazole), and an Aminoglycoside Antibiotic (Neomycin sulfate). This type of polypharmacy product is typically of synthetic or semisynthetic origin and is designed for use in situations where a single agent would be insufficient.

2. Surfaz SN Composition: The Role of the Active Ingredients

The preparation's three active ingredients—Betamethasone, Clotrimazole, and Neomycin sulfate—each play a crucial, specialized role in the medicine’s overall effect. Betamethasone, a potent corticosteroid, is clinically recognized for its ability to reduce inflammation and itching on the skin, providing rapid symptomatic relief. This action is paired with the broad antimicrobial activity of both Clotrimazole and Neomycin sulfate. Clotrimazole is an established antifungal component effective against common fungal and yeast infections. The Neomycin component, an antibiotic, is included to mitigate the risk of bacterial superinfection. These APIs are delivered through a specialized cream base or ointment base for efficient topical administration.

3. General Purpose and Differentiation

The general therapeutic purpose of Surfaz SN is to provide comprehensive management for dermatoses where inflammation is compounded by concurrent fungal and bacterial pathogens, such as an inflamed fungal lesion complicated by minor surface bacteria. This combination is strategically positioned as a single, multi-action solution for patients presenting with these mixed symptoms, requiring a targeted, three-pronged approach. The core benefit is its broad-spectrum action, which aims to resolve the inflammatory reaction while simultaneously controlling or eliminating the microbial causes contributing to the condition.

Regulatory References

  1. National Institutes of Health (NIH)

What side effects are possible with Surfaz SN?

Possible Side Effects and Safety Information

The safety profile of this triple combination (Betamethasone, Clotrimazole, Neomycin sulfate) is characterized by local skin reactions and the rare potential for serious systemic effects due to the absorption of the corticosteroid and antibiotic components. All adverse effects and safety characteristics are derived from officially documented regulatory labeling.

Adverse Reactions by System and Frequency

The most frequently reported adverse reactions are typically localized to the skin (Skin and Subcutaneous Tissue Disorders). Effects classified as common in regulatory documents include a burning sensation, stinging, itching, irritation, and dryness at the application site. Effects such as folliculitis, hypopigmentation, and skin atrophy are generally classified as uncommon or rare.

Serious Systemic Considerations

Serious adverse reactions, though rare with proper topical use, are linked to systemic absorption, which affects multiple System-Organ Classes.

  • Endocrine System: Systemic absorption of the corticosteroid may cause suppression of the HPA axis (Hypothalamic-Pituitary-Adrenal axis) and, rarely, the clinical presentation of Cushing's syndrome.
  • Auditory and Renal Systems: Absorption of the Neomycin component carries a documented risk of ototoxicity (damage to hearing/balance) and nephrotoxicity (kidney damage).

Population-Specific and Duration-Related Safety Patterns

Regulatory information explicitly notes the increased susceptibility of pediatric patients and infants to the systemic effects of the corticosteroid, including HPA axis suppression and potential linear growth retardation, due to enhanced absorption. Furthermore, adverse reactions like skin atrophy and systemic effects are strongly associated with prolonged use or application to large surface areas, broken skin, or under occlusion.

Overdose and Emergency Response

Overdose Map: Overdose and when to seek help — Official Regulatory Information for Surfaz SN

Feature Regulatory Documentation
Documented overdose presentations Manifestations of HPA axis suppression and Cushing's syndrome; clinical signs of Neomycin nephrotoxicity, neurotoxicity (e.g., convulsions), and irreversible ototoxicity (hearing loss).
Physiological systems affected (as stated in label) Endocrine system (HPA axis), Renal system, Auditory/Vestibular systems, and Neuromuscular system (risk of blockade).
Dose-related or exposure-related factors (if applicable) Systemic toxicity is linked to prolonged use, excessive application, or use on large surface areas due to enhanced absorption of the Betamethasone and Neomycin components.
Population-specific overdose notes (if applicable) Pediatric patients are more susceptible to systemic effects, including HPA-axis suppression and growth retardation. Patients with impaired renal function face an increased risk of Neomycin-related organ toxicity.
Emergency-response statements (as written in official documents) If HPA axis suppression is confirmed, the medicine should be discontinued gradually under medical supervision. If severe signs of Neomycin systemic absorption are suspected, use of the product should be stopped. Treatment is symptomatic and supportive.
When immediate medical help is required (label-derived phrasing only) Seek immediate medical attention for symptoms indicative of a serious allergic reaction (e.g., swelling of the face, throat, or tongue, or trouble breathing). The product may be harmful if swallowed.

Overdose classifications (high-level)

Classification Regulatory Documentation
Severity classification (as defined in official documents) Outcomes are classified as severe due to the potential for irreversible damage (ototoxicity) and life-threatening complications (respiratory paralysis).
Regulatory basis (EMA / FDA / etc.) Based on official Prescribing Information and authorized SmPCs.
Overdose-context constraints (as defined in official documents) Toxic effects arise from the systemic absorption of the corticosteroid and aminoglycoside components; management involves monitoring.

Resulting overdose structure

Official overdose statements:

  • Suspected systemic absorption of Neomycin necessitates monitoring of renal function, hearing acuity, and neuromuscular functions to detect potential ototoxicity or nephrotoxicity.
  • Laboratory evaluation for HPA axis suppression includes procedures such as the ACTH stimulation test, morning plasma cortisol, and urinary-free cortisol tests.
  • For confirmed HPA axis suppression, medical supervision is required for a gradual withdrawal of the topical product.
  • Immediate medical attention is required for any signs of a serious allergic reaction or if the product is swallowed.

Connection to the overall overdose profile (2–4 sentences): The regulatory overdose profile details severe systemic risks from the Betamethasone and Neomycin components, which can lead to documented endocrine, renal, and auditory damage. This framework mandates immediate medical attention for acute, life-threatening symptoms and outlines specific monitoring requirements (e.g., ACTH testing, hearing checks) and procedural steps (e.g., gradual discontinuation) for managing chronic, exposure-related toxicity, strictly as defined by official health authorities.

Therapeutic Uses of Surfaz SN

What Surfaz SN Treats: Main Uses and Benefits

This medication is commonly used across conditions characterized by periods of heightened symptoms where the primary irritation and inflammation are associated with multiple microbial components. The formulation is used in various skin infections and associated inflammation.

It is relevant for managing symptoms that interfere with daily comfort, specifically those associated with microbial and inflammatory processes. This includes pruritus (itching), erythema (redness), and edema (swelling) that often complicate rashes like tinea infections.

The combination is applied in clinical settings that involve acute or unstable symptom patterns in challenging anatomical locations. Applying this supportive therapy helps ease the overall symptom burden and supports general well-being during symptomatic phases.

“The primary benefit is in providing symptomatic relief during episodes marked by both microbial and inflammatory manifestations.”

Quick Fact: Symptom Support for Intense Itching This medication is generally used to help relieve distressing symptoms related to physical discomfort during flare-ups of inflamed skin infections.

Regulatory References

  1. Nigerian National Agency for Food and Drug Administration and Control (NAFDAC)

Eligibility and Restrictions for Use

Eligibility Profile: Who Can and Cannot Use Surfaz SN

This section outlines the official eligibility and non-eligibility requirements for Surfaz SN cream, strictly based on government regulatory documentation (e.g., FDA, EMA, Health Canada).

Contraindications (Must Not Use)

  • Hypersensitivity: Individuals with a known allergy or hypersensitivity to Beclomethasone, Clotrimazole, Neomycin, or any other ingredient in the formulation.
  • Infections: Patients with active viral skin infections (such as Herpes simplex or Varicella), tuberculosis of the skin, syphilitic skin infections, or fungal infections of the nails or scalp.
  • Specific Conditions: Patients with acne rosacea or perioral dermatitis.

Restricted or Conditional Use

Population Group Regulatory Status and Requirement
Children Under 12 Not Recommended/Contraindicated due to insufficient safety data and the risk of systemic absorption.
Pregnancy/Breastfeeding Use is conditional; requires a doctor's consultation and prescription, and should only be used if considered necessary.
Comorbidities Patients with diabetes, kidney disease, liver health issues, or a history of hearing problems must use the medicine with caution and under medical supervision.
Other Restrictions Application should be avoided on large skin areas or for a prolonged duration. Avoid contact with rubber contraceptive devices (condoms, diaphragms).

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Surfaz SN (Betamethasone, Clotrimazole, and Neomycin sulfate) based on the risk of systemic absorption of its active ingredients, which can be heightened by improper use or co-administration with similar agents.

Documented Interaction Restrictions

Co-use with Occlusive Dressings is restricted because they significantly enhance systemic absorption, increasing the risk of toxicity from the Betamethasone component. A restriction also applies to Latex Contraceptives (condoms or diaphragms) due to the potential for the cream or ointment base to compromise the integrity of the latex, reducing its intended functional reliability.

Pharmacodynamic and Exposure Interactions

Co-administration with Systemic Corticosteroids poses a pharmacodynamic risk of additive effects, potentially leading to Hypothalamic-Pituitary-Adrenal (HPA) axis suppression. The concurrent use of Systemic Aminoglycoside Antibiotics with the Neomycin component creates an additive risk of Ototoxicity (ear damage) and Nephrotoxicity (kidney damage), especially if the topical preparation is applied over large or compromised skin areas. The Clotrimazole component, though minimally absorbed, carries the theoretical potential for CYP3A4 and P-glycoprotein (P-gp)-mediated interactions, based on the known pharmacology of its oral form.

Population-Specific Constraints

Official labeling notes that the risk of systemic Neomycin toxicity is a formal concern in patients with Renal Impairment due to reduced clearance. Furthermore, the Pediatric Population is identified as being at an increased risk of systemic side effects due to enhanced absorption relative to body mass.

Mechanism of Action

Surfaz SN is a tripartite topical formulation comprising a corticosteroid, an azole antifungal, and an aminoglycoside antibiotic, each targeting distinct cellular and molecular processes.

Beclomethasone Dipropionate acts as a glucocorticoid receptor agonist. Upon binding, the activated complex translocates to the nucleus, modulating gene transcription. This alters the expression of numerous proteins, including the inhibition of Phospholipase A2, thereby preventing the release of arachidonic acid from membrane phospholipids. This upstream blockage of the eicosanoid cascade ultimately diminishes the synthesis and release of inflammatory mediators like prostaglandins and leukotrienes, resulting in widespread dampening of the local inflammatory signaling pathways and concurrent local vasoconstriction.

Clotrimazole functions as an antifungal by acting as a non-competitive inhibitor of 14-alpha demethylase, a cytochrome P450 enzyme essential for the conversion of lanosterol to ergosterol. Ergosterol is a vital structural component of the fungal cell membrane. The inhibition of its synthesis compromises fungal cell membrane integrity, leading to increased permeability and leakage of intracellular components.

Neomycin is an aminoglycoside antibiotic. It binds to the 30S ribosomal subunit of susceptible bacterial cells, specifically interfering with the formation of the initiation complex and causing misreading of the mRNA template. This action disrupts bacterial protein synthesis, leading to the generation of aberrant, non-functional polypeptides, ultimately inhibiting bacterial cellular replication and growth.

Dosage and Administration Information

How to Use Surfaz SN

Surfaz SN (Betamethasone, Clotrimazole, Neomycin combination) is a topical preparation intended solely for application to the surface of the skin. Its administration follows standard application procedures to ensure consistent use.

Standard Administration Protocol

Usage Principle Instruction
Route of Administration Restricted to cutaneous (external topical) use only.
Dosing Frequency Typically applied twice daily (e.g., morning and evening).
Application Method A thin film of the medication is gently rubbed into the affected and surrounding skin areas after the skin has been cleaned and dried.

Duration and Limitations

The treatment course is time-limited and should not be prolonged beyond the specified period. For example, for common fungal infections on the body (Tinea Corporis or Tinea Cruris), the maximum recommended duration of use is generally two weeks. Use in the groin area requires loose-fitting clothing.

Key restrictions govern its procedural application. The treated skin area must not be covered with occlusive dressings, bandages, or wraps unless specifically directed by a healthcare professional. Furthermore, the cream is not for use on the face, under the arms, or in the diaper area of infants. The total amount applied per week should not exceed 45 grams of the formulation. Use is not recommended for individuals under 17 years of age. If a dose is missed, it should be applied as soon as remembered, but never doubled.

Recent Clinical Evidence

Research evidence / Overview of studies for Surfaz SN

Evidence for Use in Inflammatory, Mixed Skin Infections

Research exploring this topical combination examined its use in conditions involving periods of heightened symptoms, specifically dermatoses that present with concurrent fungal and bacterial components. The evidence base includes short-term Randomized Controlled Trials (RCTs) and comparative clinical studies involving symptoms that may fluctuate. Studies were conducted to explore the formulation’s role in specific fungal conditions, such as tinea infections, where inflammation and the potential for bacterial presence were a factor.

Research focused on outcomes linked to inflammatory or irritative states, such as changes in objective clinical signs like redness (erythema), scaling, and fissuring. Simultaneously, studies evaluated measures of physical discomfort, including patient-reported measures of perceived discomfort like itching (pruritus) and burning. These studies report how symptoms evolved in the observed populations over brief, defined time intervals.

Design of Key Clinical Trials

The key clinical trials were often short-term and comparative, focusing on measuring changes during the treatment phase. Research examined populations composed mainly of adults and adolescents presenting with moderate to severe expressions of the target conditions.

The treatment phase for the studies was typically limited to 2 to 4 consecutive weeks, with a final study visit up to six weeks from the start of the study. This methodology explores short-term symptom changes and how readily measurable clinical signs change during the period of active application. Outcomes also included laboratory tests to monitor mycological status, documenting fungal status endpoints in the observed populations.

Long-term Follow-up and Durability of Outcomes

Research concerning the extended effects of this topical combination is limited. Long-term effects are not fully established because follow-up durations in the major clinical trials were limited, typically concluding just two weeks after the treatment ended.

Studies provide limited information about the persistence of initial symptom changes or the rate at which conditions may recur after the short treatment course. While the initial evidence describes short-term patterns, there is limited information for long-term outcomes.

Key Studies & References

  1. NAFDAC Summary of Product Characteristics (SMPC) - Triple Combination (Clotrimazole, Betamethasone, Neomycin)
  2. Comparative study of a triple-combination topical preparation in corticosteroid responsive dermatoses and/or cutaneous fungal and/or bacterial infections
  3. Principles of Antimicrobial Therapy

Frequently Asked Questions (FAQ)

Common questions about Surfaz SN (FAQ)

Q: How should I store this medication, and what happens if I miss a dose?

A: The official product information provides specific instructions on how to properly store Surfaz SN, including the required temperature range. The product labeling also includes directions regarding missed doses, which outline whether the dose should be taken or skipped to remain consistent with the regular schedule.

Q: Does this medication make you sleepy?

A: The drug's official labeling lists somnolence, or drowsiness, among its reported adverse reactions. The Warnings and Precautions section of the label often addresses the implications of somnolence on activities that require concentration, such as driving or operating machinery.

Q: Is this medication safe to take long-term, and what are the effects after one year?

A: The approved Indications and Usage section specifies the condition(s) Surfaz SN is approved to treat. Official information regarding the approved duration of use is summarized in the labeling, along with the safety profile and effects observed during clinical studies that may have included longer treatment periods.

Q: Is it safe to drink alcohol while taking this medication?

A: The official product labeling addresses the use of alcohol while taking Surfaz SN. This section provides specific information regarding any known potential drug interactions or altered effects that may occur when alcohol is consumed.

Q: Can children 2 years old use this medication?

A: The official labeling specifies the approved age ranges for which Surfaz SN is indicated. If the 2-year-old population is not listed in the approved indications, the official documents do not contain dosage or use information for this specific age group.

How should Surfaz SN be stored and disposed of?

How to Store and Dispose of Surfaz SN?

Regulatory documents mandate specific conditions to maintain the stability and quality of Surfaz SN Cream.

Official Storage Requirements

Condition Requirement
Temperature Store below 30 C and keep the product from freezing.
Environment Maintain storage in a dry place and protect from sunlight.
Container Keep the cream in its original container and ensure the container is tightly closed when not in use.
Child Safety Store the medicine out of the sight and reach of children and pets.

Disposal Instructions

Any unused or expired Surfaz SN must be disposed of in accordance with local regulations. It is important to prevent accidental consumption by pets or children. Disposal must also avoid release to the environment, and the product should not be thrown away in ordinary household trash unless specifically instructed by local drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Surfaz SN found in:

A-Z Index: